Replimune Group (NASDAQ:REPL) Stock Jumps 5.3% – Here’s What Happened

Posted by Stanley Muller on Oct 28th, 2026

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) shares traded up 5.3% on Monday. The company traded as high as $12.14 and last traded at $12.0640. Approximately 201,064 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 4,305,646 shares. The stock had previously closed at $11.46.

Analysts Set New Price Targets

Several research firms have issued reports on REPL. Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $11.00 to $17.00 in a report on Tuesday, August 4th. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Wolfe Research raised shares of Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective on the stock in a report on Friday, August 7th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Replimune Group in a research report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.

Get Our Latest Analysis on Replimune Group

Replimune Group Price Performance

The company’s 50 day simple moving average is $13.45 and its two-hundred day simple moving average is $9.21.

Replimune Group (NASDAQ:REPL – Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24. Equities research analysts expect that Replimune Group, Inc. will post -2.82 earnings per share for the current year.

Insider Activity

In other news, insider Konstantinos Xynos sold 11,447 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the transaction, the insider owned 224,215 shares of the company’s stock, valued at $2,908,068.55. This represents a 4.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $510,252.77. Following the completion of the transaction, the chief executive officer directly owned 708,151 shares in the company, valued at approximately $9,184,718.47. The trade was a 5.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 79,124 shares of company stock valued at $1,038,364. Company insiders own 5.40% of the company’s stock.

Institutional Trading of Replimune Group

A number of large investors have recently bought and sold shares of the business. Allworth Financial LP acquired a new position in Replimune Group during the 2nd quarter worth approximately $62,000. Essential Partners LLC grew its stake in Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after buying an additional 5,624 shares during the last quarter. Legal & General Group Plc bought a new position in Replimune Group during the 2nd quarter worth $85,000. WINTON GROUP Ltd acquired a new position in shares of Replimune Group during the 2nd quarter worth approximately $115,000. Finally, E Fund Management Co. Ltd. bought a new stake in shares of Replimune Group during the 2nd quarter valued at $119,000. 92.53% of the stock is owned by institutional investors.

About Replimune Group

(Get Free Report)

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.